Public Policy Statement on Prescription Drug Monitoring Programs (PDMPs)

Public Policy Statement on E-Cigarettes

Public Policy Statement on the Role of Recovery in Addiction Care

During ASAM’s 2018 Annual Conference, ASAM’s Board of Directors approved of three new policy statements: Prescription Drug Monitoring Programs (PDMPs), E-Cigarettes, and the Role of Recovery in Addiction Care.

The Policy Statement on PDMPs addresses a wide scope of issues including whether prescribers and dispensers should be required to enroll in and query state's PDMPs, whether state PDMPs should include methadone and buprenorphine from OTPs, and whether the total opioid MME should include buprenorphine. The Policy Statement on E-Cigarettes includes recommendations on the FDA regulation of e-cigarettes, targeted marketing to young people, and research into the long-term potential for harms from the use of e-cigarettes. Lastly, the Role of Recovery in Addiction Care Policy Statement discusses abstinence and recovery, language and terminology pertaining to remission and recovery, and performance and quality of care measures.